Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AND017 for the Treatment of Anemia of Cancer in Patients Not Receiving Chemotherapy
NCT06075043Phase 2Not yet recruiting
- Sponsor
- Kind Pharmaceuticals LLC
- Start
- Dec 2027
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of AND017 in cancer-related anemia (CRA) (3 arms), sponsored by Kind Pharmaceuticals LLC. Primary endpoint: Percentage of responding patients at 6 weeks. Planned start Dec 2027; status: not yet recruiting.
02
Drugs
AND017
03
Conditions
cancer-related anemia (CRA)
Beyond the preview
Go deeper on NCT06075043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075043.